Form 4: Corcept Officer Boosts Stake with Share Purchases

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, increased his direct beneficial ownership of common stock through a purchase plan and restricted stock awards, while also having shares withheld for tax obligations.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc. (CORT), reported transactions in the company's common stock.
• On March 2, 2026, Lyon purchased 398 shares of common stock at a price of $35.97 per share through a purchase plan under the 2024 Incentive Award Plan.
• Also on March 2, 2026, Lyon was granted 398 unvested restricted stock awards (RSAs) at a price of $0.00 per share, which will vest on the one-year anniversary of the grant date.
• On March 3, 2026, 89 shares were withheld by the Issuer at a price of $35.97 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Lyon's direct beneficial ownership of common stock stands at 11,230 shares.
• This total includes previously granted unvested restricted stock awards from March 3, 2025 (216 shares), June 2, 2025 (749 shares), September 2, 2025 (200 shares), and December 1, 2025 (178 shares).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. An officer increasing their stake, even partially through a purchase plan, generally indicates confidence in the company's future performance, although the transaction size is not exceptionally large.

Positives

• Joseph Douglas Lyon, a key officer, increased his direct beneficial ownership of Corcept Therapeutics common stock by a net of 707 shares, signaling confidence in the company.
• The acquisition of shares through a purchase plan and restricted stock awards aligns the officer's interests with those of shareholders.

Negatives

• 89 shares were disposed of to cover tax withholding obligations, which is a routine event but represents a reduction in direct ownership.

Risks

• The newly acquired restricted stock awards and previously granted unvested restricted stock awards are subject to vesting conditions, typically requiring continued employment or satisfaction of other requirements for one year from the grant date.

Future Outlook

The unvested restricted stock awards, including the 398 shares granted on March 2, 2026, are expected to vest on their respective one-year anniversaries, provided the Reporting Person satisfies certain requirements, indicating future ownership and alignment.

Management Comments

• Joseph Douglas Lyon participated in a purchase plan under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan, acquiring additional shares of common stock.
• Lyon received unvested restricted stock awards, which are subject to vesting conditions over a one-year period.

Industry Context

StockSavvy.ai notes that insider purchases, even of a modest size, can be interpreted by the market as a positive signal, reflecting management's belief in the company's future prospects. This transaction is a routine disclosure of an executive's equity activity.

Corporate Governance

Stakeholder Impact

• Shareholders may view the increase in insider ownership as a positive indicator of management's belief in the company's value and future performance.
• Employees, particularly those participating in similar incentive plans, may see this as a reaffirmation of the company's commitment to equity-based compensation.

Next Steps

• The 398 unvested restricted stock awards granted on March 2, 2026, are expected to vest on March 2, 2027, subject to the Reporting Person remaining the beneficial owner of the Purchase Plan Shares through that date.
• Other previously granted unvested restricted stock awards will vest on their respective one-year anniversaries, provided the Reporting Person satisfies certain requirements.

Key Dates

Keywords

Corcept Therapeutics, CORT, Insider Transaction, Form 4, Stock Purchase, Restricted Stock Awards, Executive Compensation, Beneficial Ownership